PPARG and systemic sclerosis: Dual CB2/PPARγ agonists such as VCE-004.8 and JBT-101 (Ajulemic acid, Lenabasum) have alleviated skin fibrosis and inflammation in SSc models (Rio et al., 2018; García-Martín et al., 2019).